Gabriela Hossu1, Franois Kauffmann2, Nicolas Courouble1, Caroline Henry3, Mikael Jokic4, Antoine Coquerel5, Pierre Denise6, Jean-Marc Constans1,7
1MRI Unit, Caen University Hospital, Caen, Normandy, France; 2LMNO CNRS UMR 6139, Caen University, Caen, Normandy, France; 3Hematology Service, Caen University Hospital, Caen, Normandy, France; 4Infant Surgery, Caen University Hospital, Caen, Normandy, France; 5Pharmacology, Caen University Hospital, Caen, Normandy, France; 6Physiology, Caen University Hospital, Caen, Normandy, France; 7CERVOxy and UMR6232 CI-NAPS , Cyceron, Caen, Normandy, France
Using prior knowledge for in vitro studies performed under the same conditions as patient examinations may improve identification of lesser-known components such as neurogenesis peaks, apoptosis biomarkers or medications. We studied in vitro measurements acquired under in vivo conditions using a test object composed of three separate compartments for Mannitol drug and using 1% TMS in CDCl3 and Choline as internal references. We propose a new approach to analyzing and validating reproducibility of spectroscopic patterns. Consequently, in vivo identification of Mannitol accumulation in human brain pathologies can be measured, for the first time, with a higher level of precision.